CN106198985B - For detecting the ELISA kit and application method of castration-resistant prostate cancer - Google Patents
For detecting the ELISA kit and application method of castration-resistant prostate cancer Download PDFInfo
- Publication number
- CN106198985B CN106198985B CN201610770860.2A CN201610770860A CN106198985B CN 106198985 B CN106198985 B CN 106198985B CN 201610770860 A CN201610770860 A CN 201610770860A CN 106198985 B CN106198985 B CN 106198985B
- Authority
- CN
- China
- Prior art keywords
- prostate cancer
- elisa
- castration
- resistant prostate
- hole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a kind of ELISA kit and application method for being used to detect castration-resistant prostate cancer, it is related to immunoassay.Kit of the present invention includes FG gamma antibodies, and detects the FG γ contents in serum by double antibody sandwich ELISA, determines whether patient has progressed to castration-resistant prostate cancer.The effective product for solving the problems, such as to detect castration-resistant prostate cancer in the prior art of the invention or method poor specificity, accuracy be not high.Kit of the present invention diagnoses castration-resistant prostate cancer according to the content of FG γ in serum, has higher sensitivity and specificity.Kit of the present invention quick, reasonable simple to operate, can improve the diagnosis efficiency of castration-resistant prostate cancer, have broad application prospects.
Description
Technical field
The present invention relates to immunoassay, specifically a kind of ELISA reagents for being used to detect castration-resistant prostate cancer
Box and application method.
Background technology
Prostate cancer is the most common malignant tumour of male urinary system, relatively conventional in American-European countries, is that male is most normal
The malignant tumour seen, account for the second of all malignant tumours.China is the relatively low country of traditional prostate-cancer incidence, still
Recently as the raising of living standards of the people, the change of environment, and the raising of disorder in screening popularity rate, the prostate in China
Cancer morbidity rises year by year.Prostate cancer turns into a kind of important diseases for threatening China's men's health, by more
Come more concern and attention.
One of most important therapeutic modality of prostate cancer is exactly castration therapy, including medicine anti-androgen therapy and operation
Castration, suppress the growth of tumour in a manner of preventing androgen from being attached on androgen receptor.In prostate cancer in early days,
Castration has preferable effect, but after treatment after a while, prostate cancer be gradually converted into androgen it is non-according to
Rely property, no longer sensitive to castration, the state of an illness deteriorates once again, i.e. castration-resistant prostate cancer（CRPC）Stage.Castration is supported
The pathogenesis of refractory prostate cancer it is not immediately clear, be prostate cancer basis and clinic also without preferable treatment method
The problem in field.
The diagnosis for castration-resistant prostate cancer does not have good method at present, mainly by monitoring prostate
The change of specific antigen and testosterone, and according to clinical manifestation come comprehensive descision, shortage preferably specificity, it is impossible to exactly
Judge castration-resistant prostate cancer.Early find castration-resistant prostate cancer, the formulation to anaphase strategy and
Prostate cancer is more in depth recognized from molecular level, there is very important meaning.
The content of the invention
The present invention is exactly to solve the product for detecting castration-resistant prostate cancer in the prior art or method specificity
Difference, the problem of accuracy is not high, a kind of ELISA kit and the use for being used to detect castration-resistant prostate cancer proposed
Method.
The present invention is realized according to following technical scheme.
A kind of ELISA kit for being used to detect castration-resistant prostate cancer, the kit include FG gamma antibodies, with
And the detection reagent needed for double antibody sandwich ELISA.
A kind of ELISA kit for being used to detect castration-resistant prostate cancer, the kit include coating FG γ and resisted
ELISA ELISA Plates, standard items, standard items ＆ sample diluting liquids, the FG gamma antibodies of biotin labeling, the Avidin of body mark peppery
One or more in root peroxidase, cleaning solution, substrate solution, reaction terminating liquid, overlay film.
Detect the serum that sample is patients with prostate cancer.
A kind of above-mentioned application method for being used to detect the ELISA kit of castration-resistant prostate cancer, including following step
Suddenly：
I, gathers patients with prostate cancer whole blood sample, centrifuging and taking supernatant；
II, sets blank well, gauge orifice, testing sample hole respectively, and blank well adds standard items sample diluting liquid, remaining hole difference
Add standard items or testing sample, mix；ELISA Plate adds overlay film, is incubated；
III, discards liquid in hole, dries；The FG gamma antibodies of biotin labeling are added per hole, ELISA Plate adds overlay film, incubates；
IV, discards liquid in hole, dries, and washs ELISA Plate, then dry；
V, adds the horseradish peroxidase of Avidin mark per hole, and ELISA Plate adds overlay film, incubates；
VI, discards liquid in hole, dries, and washs ELISA Plate, then dry；
VII, adds substrate solution per hole, and ELISA Plate adds overlay film, and lucifuge is incubated；
VIII, adds reaction terminating liquid per hole；
The OD values in each hole are measured under Ⅸ, 450nm wavelength；
Ⅹ, calculates serum sample FG γ detected value according to the OD values of standard items, and judges its size with decision threshold
Relation.
In the step I whole blood sample in room temperature place 0 ~ 4 hour or 0 ~ 8 DEG C overnight after 500 ~ 1500 × g centrifuge 10 ~
30 minutes.
ELISA Plate is washed in the step IV 1 ~ 5 time, soak 1-2 minutes every time；ELISA Plate is washed in step VI 3 ~ 7 times,
Immersion 1-2 minutes every time.
ELISA Plate is washed in the step IV 3 times, every time immersion 1.5 minutes；ELISA Plate is washed in step VI 5 times, every time
Immersion 1.5 minutes.
The decision threshold is 19748.73mg/ml ~ 24137.33mg/ml.
The decision threshold is 21943.03mg/ml.
Present invention obtains following beneficial effect.
It is of the invention effectively to solve the product for detecting castration-resistant prostate cancer in the prior art or method specificity
Difference, the problem of accuracy is not high.Kit of the present invention diagnoses castration-resistant prostate cancer according to the content of FG γ in serum,
With higher sensitivity and specificity.Kit of the present invention quick, reasonable simple to operate, before castration-resistant being improved
The diagnosis efficiency of row gland cancer, has broad application prospects.
Brief description of the drawings
Fig. 1 is that FG γ are detected in the non-castration-resistant prostate cancer of the present invention and castration-resistant prostate cancer patients serum
The statistical result figure of value；
Fig. 2 is the ROC curve figure that the present invention diagnoses castration-resistant prostate cancer with serum FG γ levels.
Embodiment
Below in conjunction with the accompanying drawings and embodiment the present invention is described further.
A kind of ELISA kit for being used to detect castration-resistant prostate cancer, the kit include FG gamma antibodies, with
And the detection reagent needed for double antibody sandwich ELISA.
A kind of ELISA kit for being used to detect castration-resistant prostate cancer, the kit include coating FG γ and resisted
ELISA ELISA Plates, standard items, standard items ＆ sample diluting liquids, the FG gamma antibodies of biotin labeling, the Avidin of body mark peppery
One or more in root peroxidase, cleaning solution, substrate solution, reaction terminating liquid, overlay film.
Detect the serum that sample is patients with prostate cancer.
A kind of above-mentioned application method for being used to detect the ELISA kit of castration-resistant prostate cancer, including following step
Suddenly：
I, gathers serum of patients with prostate cancer：Whole blood sample in room temperature place 2 hours or 4 DEG C overnight after 1000 × g from
The heart 20 minutes, take supernatant i.e. detectable, the test tube for collecting blood should be disposable apyrogeneity, endotoxin-free test tube.
Before experiment starts, each reagent all should be balanced to room temperature；When reagent or sample preparation, it is both needed to fully mix, and as far as possible
Avoid bubbling.
It is coated with the ELISA ELISA Plates of FG gamma antibodies：The concentration of coated antibody is 1~100 μ g/ml, preferably 10 μ g/ml.
Standard items：FG γ 1000ng, are configured to following concentration： 1000、500、250、125、62.5、31.25、
15.625、0ng/mL。
Standard items ＆ sample diluting liquids：100ml PBS, BSA 2g are added, to final concentration 2%
The FG gamma antibodies of biotin labeling：0~100 μ g/ml, preferably 10 μ g/ml.
The horseradish peroxidase of Avidin mark：0.0001~0.0005 mg/ml
Cleaning solution:0.05%Tween-20 0.5ml are added in PBS 1000ml.
Substrate solution：TMB (tetramethyl benzidine).
Reaction terminating liquid：2M H2SO4。
II, is loaded：Blank well, gauge orifice, testing sample hole are set respectively.Blank well adds the μ of standard items sample diluting liquid 100
L, remaining hole add standard items or the μ L of testing sample 100 respectively, have been careful not to bubble, and sample is added on into ELISA Plate bottom during sample-adding,
Hole wall is not touched as far as possible, gently rocks mixing.ELISA Plate overlay film is given, 37 DEG C are incubated 90 minutes.
III, discards liquid, dries, without washing.The μ L of FG gamma antibodies 100 of biotin labeling, enzyme are added in each hole
Target adds overlay film, and 37 DEG C incubate 1 hour.
IV, discards liquid in hole, dries, board-washing 3 times, soaks every time 1-2 minutes, and about 350 μ L/ dry per hole
And patted on blotting paper and pat dry liquid in hole.
V, adds the μ L of horseradish peroxidase 100 that Avidin marks per hole, and plus overlay film, 37 DEG C incubate 30 minutes.
VI, discards liquid in hole, dries, board-washing 5 times, method is the same as step IV.
VII, adds the μ L of substrate solution (TMB) 90 per hole, and ELISA Plate is incubated 15 minutes or so plus 37 DEG C of lucifuges of overlay film
（Take the circumstances into consideration to shorten or extend according to actual colour developing situation, but may not exceed 30 minutes.When obvious gradient occurs in gauge orifice, i.e.,
It can terminate）.
VIII, adds the μ L of reaction terminating liquid 50 per hole, and terminating reaction, now blueness is vertical turns yellow.The addition sequence of terminate liquid
It should try one's best identical with the addition sequence of substrate solution.
Ⅸ, uses ELIASA immediately（SPECTRA max plus384）Optical density in each hole of 450nm wavelength measurements（OD
Value）.
Ⅹ, substitutes into equation according to the OD values of standard items and calculates serum sample FG γ detected value, and judges itself and decision threshold
The magnitude relationship of value.
If FG γ detected values are more than or equal to decision threshold, judge that patient has progressed to castration-resistant prostate cancer,
Judge that patient does not progress to castration-resistant prostate cancer if FG γ detected values are less than decision threshold.Detected with FG γ in serum
It is decision threshold to be worth for 19748.73mg/ml ~ 24137.33mg/ml, preferably 21943.03mg/ml.
Embodiment 1
The present embodiment is using FG γ detected values 21943.03mg/ml as judgment threshold, if FG γ detected values are more than or equal to
During 21943.03mg/ml, then judge that patient has progressed to castration-resistant prostate cancer, if FG γ detected values are less than
21943.03mg/ml then judge that patient does not progress to castration-resistant prostate cancer.In 86 samples of the present embodiment, use
The sensitiveness of kit diagnosis castration-resistant prostate cancer of the present invention is 69%, and specificity is 86.4%.
The inspection value of the serum sample of the present embodiment is drawn in Fig. 1, and two groups are compared P<0.05, difference has statistics meaning
Justice.
Fig. 2 is the ROC curves that are diagnosed as castration-resistant prostate cancer of FG γ, and abscissa is 1- specificities, ordinate
For sensitivity, AUC=0.808, wherein ROC represent TG-AUC.It can be seen that sensitivity reaches 69%, specificity
Reach 86.4%.
It can be seen that detecting the content of FG γ in serum of patients with prostate cancer using the present invention, castration can be rapidly and accurately diagnosed
Repellence prostate cancer, there is higher sensitivity and specificity.
Claims (7)
- Purposes of the 1.FG gamma antibodies in preparation is used to detect the ELISA kit of castration-resistant prostate cancer, its feature exist In：The kit includes FG gamma antibodies, is detected using the content of FG γ in double-antibodies sandwich ELISA detection serum Gesture repellence prostate cancer, decision threshold are 19748.73mg/ml ~ 24137.33mg/ml.
- 2. FG gamma antibodies according to claim 1 are preparing the ELISA reagents for detecting castration-resistant prostate cancer Purposes in box, it is characterised in that：The kit includes ELISA ELISA Plates, standard items, the standard items ＆ of coating FG gamma antibodies It is sample diluting liquid, the FG gamma antibodies of biotin labeling, the horseradish peroxidase of Avidin mark, cleaning solution, substrate solution, anti- Answer the one or more in terminate liquid, overlay film.
- 3. FG gamma antibodies according to claim 1 are preparing the ELISA reagents for detecting castration-resistant prostate cancer Purposes in box, it is characterised in that：The application method for being used to detect the ELISA kit of castration-resistant prostate cancer, Comprise the following steps：I, gathers patients with prostate cancer whole blood sample, centrifuging and taking supernatant；II, sets blank well, gauge orifice, testing sample hole respectively, and blank well adds standard items sample diluting liquid, and mark-on is distinguished in remaining hole Quasi- product or testing sample, mix；ELISA Plate adds overlay film, is incubated；III, discards liquid in hole, dries；The FG gamma antibodies of biotin labeling are added per hole, ELISA Plate adds overlay film, incubates；IV, discards liquid in hole, dries, and washs ELISA Plate, then dry；V, adds the horseradish peroxidase of Avidin mark per hole, and ELISA Plate adds overlay film, incubates；VI, discards liquid in hole, dries, and washs ELISA Plate, then dry；VII, adds substrate solution per hole, and ELISA Plate adds overlay film, and lucifuge is incubated；VIII, adds reaction terminating liquid per hole；The OD values in each hole are measured under Ⅸ, 450nm wavelength；Ⅹ, calculates serum sample FG γ detected value according to the OD values of standard items, and judges its magnitude relationship with decision threshold, The decision threshold is 19748.73mg/ml ~ 24137.33mg/ml.
- 4. FG gamma antibodies according to claim 3 are preparing the ELISA reagents for detecting castration-resistant prostate cancer Purposes in box, it is characterised in that：In the step I whole blood sample in room temperature place 0 ~ 4 hour or 0 ~ 8 DEG C overnight after 500 ~ 1500 × g is centrifuged 10 ~ 30 minutes.
- 5. FG gamma antibodies according to claim 3 are preparing the ELISA reagents for detecting castration-resistant prostate cancer Purposes in box, it is characterised in that：ELISA Plate is washed in the step IV 1 ~ 5 time, soak 1-2 minutes every time；Washed in step VI Wash ELISA Plate 3 ~ 7 times, soak 1-2 minutes every time.
- 6. FG gamma antibodies according to claim 5 are preparing the ELISA reagents for detecting castration-resistant prostate cancer Purposes in box, it is characterised in that：ELISA Plate is washed in the step IV 3 times, every time immersion 1.5 minutes；Washed in step VI ELISA Plate 5 times, soak 1.5 minutes every time.
- 7. FG gamma antibodies according to claim 3 are preparing the ELISA reagents for detecting castration-resistant prostate cancer Purposes in box, it is characterised in that：The decision threshold is 21943.03mg/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610770860.2A CN106198985B (en) | 2016-08-31 | 2016-08-31 | For detecting the ELISA kit and application method of castration-resistant prostate cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610770860.2A CN106198985B (en) | 2016-08-31 | 2016-08-31 | For detecting the ELISA kit and application method of castration-resistant prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106198985A CN106198985A (en) | 2016-12-07 |
| CN106198985B true CN106198985B (en) | 2018-03-27 |
Family
ID=58089813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610770860.2A Active CN106198985B (en) | 2016-08-31 | 2016-08-31 | For detecting the ELISA kit and application method of castration-resistant prostate cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106198985B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102460174A (en) * | 2009-05-14 | 2012-05-16 | 牛津大学之校长及学者 | Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers |
| CN104062436A (en) * | 2014-06-06 | 2014-09-24 | 上海良润生物医药科技有限公司 | Application of FXYD in preparation of marker for diagnosing and indicating lung cancer and FXYD double-antibody sandwich ELISA (enzyme-linked immune sorbent assay) detection kit |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013524783A (en) * | 2010-04-02 | 2013-06-20 | ベリデックス・エルエルシー | Gene-based prediction of PSA recurrence for patients with localized prostate cancer |
| NZ704487A (en) * | 2012-07-27 | 2018-05-25 | Aragon Pharmaceuticals Inc | Methods and compositions for determining resistance to androgen receptor therapy |
| CN105779599B (en) * | 2016-04-05 | 2020-09-11 | 上海美吉生物医药科技有限公司 | Kit for detecting metastatic castration resistant prostate cancer drug resistance |
-
2016
- 2016-08-31 CN CN201610770860.2A patent/CN106198985B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102460174A (en) * | 2009-05-14 | 2012-05-16 | 牛津大学之校长及学者 | Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers |
| CN104062436A (en) * | 2014-06-06 | 2014-09-24 | 上海良润生物医药科技有限公司 | Application of FXYD in preparation of marker for diagnosing and indicating lung cancer and FXYD double-antibody sandwich ELISA (enzyme-linked immune sorbent assay) detection kit |
Non-Patent Citations (3)
| Title |
|---|
| CSB-E13319h 人血纤蛋白原γ链（FGG）ELISA Kit;厦门慧嘉生物科技有限公司;《中国化工仪器网》;20140827;1-2 * |
| The Identification of Novel Potential Injury Mechanisms and Candidate Biomarkers in Renal Allograft Rejection by Quantitative Proteomics;Tara K. Sigdel et al.;《Molecular & Cellular Proteomics》;20131212;第13卷(第2期);摘要，624页左栏倒数第2段 * |
| 纤维蛋白原基因多态性位点与血浆纤维蛋白原γ′水平及缺血性脑卒中的关系研究;虞珊珊等;《国际检验医学杂志》;20151031;第36卷(第20期);2932页、2933页1.2节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106198985A (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108548926B (en) | A kind of creatine kinase isozyme detection kit | |
| CN104039962B (en) | The mark of breast cancer diagnosis and indication | |
| CN104650234B (en) | Anti- AKR1B10 protein monoclonal antibodies and its application | |
| CN105866418B (en) | A kind of breast carcinoma three joint inspection diagnostic kit | |
| CN106290919B (en) | For detecting the ELISA kit and application method of castration-resistant prostate cancer | |
| JP2015503922A5 (en) | ||
| WO2016011852A1 (en) | Bladder tumor-associated antigen detection kit | |
| CN106018829A (en) | Testing reagent for serum amyloid protein A and preparation method of testing reagent | |
| CN109669044A (en) | Fluorescence immunoassay absorption detection kit based on double-colored quantum dot joint-detection SAA and CRP and preparation method thereof | |
| CN105548547A (en) | Flow type array immunoassay kit for detecting lung cancer markers based on flow cytometry | |
| KR20100104110A (en) | Marker for diagnosis of breast cancer comprising thioredoxin 1, and diagnosis kit of breast cancer using the same | |
| CN105861295A (en) | Biosensor for detecting salmonella typhimurium and preparation and detection methods | |
| CN106198985B (en) | For detecting the ELISA kit and application method of castration-resistant prostate cancer | |
| CN105548546B (en) | Lung cancer screening kit | |
| CN106405085B (en) | For detecting the ELISA kit and application method of castration-resistant prostate cancer | |
| CN106526185B (en) | For detecting the ELISA kit and detection method of castration-resistant prostate cancer | |
| CN105259348B (en) | A kind of secreting type Sema4C albumen and its application | |
| CN106771259A (en) | ELISA kit, application method and purposes for detecting Pygo2 protein contents in human serum | |
| CN104865383A (en) | Liquid phase protein chip for combined detection of five colorectal cancer markers, and preparation method thereof | |
| CN206208907U (en) | A kind of kit for troponin ELISA detections | |
| CN107746430B (en) | Preparation and application of GP 73C-terminal antigen | |
| CN104597257A (en) | Rapid myoglobin detection method and corresponding detection kit | |
| CN108226520A (en) | A kind of CK-MB detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| CN107918013A (en) | The method and kit of K Ras albumen in chemiluminescence Enzyme immunoassay circulating tumor cell | |
| CN104897750B (en) | Circulating tumor cell detection probe and preparation method and application diagnostic sensor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |